# Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

> **NCT02060383** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 249 (actual)

## Conditions studied

- Cushing's Disease
- Acromegaly

## Interventions

- **DRUG:** Pasireotide s.c.
- **DRUG:** Sitagliptin
- **DRUG:** Liraglutide
- **DRUG:** Insulin
- **DRUG:** Pasireotide LAR
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02060383
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-23
- **Primary completion:** 2018-02-05
- **Final completion:** 2018-03-26
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2019-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02060383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02060383, "Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02060383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*